نتایج جستجو برای: telaprevir

تعداد نتایج: 686  

Journal: :hepatitis monthly 0
tarik akar department of gastroenterology, school of medicine, bulent ecevit university, zonguldak, turkey; department of gastroenterology, school of medicine, bulent ecevit university, 67600 kozlu, zonguldak, turkey. tel: +90-5054192900, fax: +90-3722612392 dilek malkoc department of gastroenterology, school of medicine, bulent ecevit university, zonguldak, turkey selim aydemir department of gastroenterology, school of medicine, bulent ecevit university, zonguldak, turkey

2015
Antonia Lepida Massimo Colombo Inmaculada Fernandez Djamal Abdurakhmanov Paulo Abrao Ferreira Simone I. Strasser Petr Urbanek Alessandra Mangia José L. Calleja Wafae Iraqi Ralph DeMasi Isabelle Lonjon-Domanec Christophe Moreno Heiner Wedemeyer Vincent Wong

BACKGROUND Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan values for the prediction of safety and efficacy of telaprevir-based therapy in patients with advanced fibrosis and cirrhosis in the telap...

Journal: :Balkan medical journal 2016
Nagihan İnan Gürcan Zakir Sakçı Sıla Akhan Elif Sargın Altunok Aynur Aynıoğlu Yeşim Gürbüz Hasan Tahsin Sarisoy Gür Akansel

BACKGROUND Diffusion-weighted imaging (DWI) has become an established diagnostic modality for the evaluation of liver parenchymal changes in diseases such as diffuse liver fibrosis. AIMS To evaluate the parenchymal apparent diffusion coefficient value (ADC) changes using diffusion-weighted imaging (DWI) during telaprevir-based triple therapy. STUDY DESIGN Diagnostic accuracy study. METHOD...

Journal: :Clinical therapeutics 2012
Samuel James Matthews Jason W Lancaster

BACKGROUND Telaprevir is a hepatitis C NS3/4A protease inhibitor approved by the US Food and Drug Administration as part of combination therapy for the management of chronic hepatitis C virus (HCV) genotype 1 infection. OBJECTIVE The article reviews published literature on telaprevir, including its chemistry, mechanism of action, resistance, pharmacodynamic and pharmacokinetic properties, dru...

2015
Eduardo Mastrangelo Marinho Falcão Beatriz Moritz Trope Mariana Marteleto Godinho Leonardo Hoehl Carneiro João Marcello de Araujo-Neto Cristiane Alves Villela Nogueira Marcia Ramos-e-Silva

Hepatitis C virus (HCV) chronically infects 0.5-3% of the world population. A large group of patients develop cirrhosis and its complications. Since 2011, telaprevir and boceprevir are used, improving the disease evolution. One of the main side effects of these drugs is skin eruption. We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with tel...

2013
Christoph R. Werner Daniel P. Egetemeyr Ulrich M. Lauer Silvio Nadalin Alfred Königsrainer Nisar P. Malek Christoph P. Berg

Management of recurrent Hepatitis C virus (HCV) infection following liver transplantation remains a major challenge. In non-transplanted HCV genotype 1 patients, the introduction of protease inhibitor-based regimens has significantly increased the rate of sustained virological response. In this follow-up study, on the first published cohort of post-liver transplant patients treated with telapre...

2014
Anca Streinu-Cercel Oana Săndulescu Daniela Manolache Dragoş Florea Dan Oțelea Adrian Streinu-Cercel

Results We assessed data from 12 patients (gender ratio 1:1), of which 10 had HCV monoinfection and 2 had HCV+HIV coinfection. The mean age was 43.8 ± 16.5 years (range 19-71 years). Eleven patients were infected with HCV genotype 1b, and one patient had been coinfected with genotype 2a/2c but had spontaneously cleared 2a infection and was now monoinfected with HCV 2c. Only one patient had IL28...

Journal: :Hepatology 2011
Andrew J Muir Fred F Poordad John G McHutchison Mitchell L Shiffman Thomas Berg Peter Ferenci E Jenny Heathcote Jean-Michel Pawlotsky Stefan Zeuzem Henk W Reesink Geoffrey Dusheiko Emily C Martin Shelley George Robert S Kauffman Nathalie Adda

UNLABELLED Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment. This study evaluated the safety and efficacy of telaprevir-based treatment in combination with PR in well-characterized patients who did not achieve SVR in the control arms of three Phase II clinical trials....

Journal: :Journal of Hepatology 2012

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید